FDA grants quick review for 3 psychedelic drug trials
FDA, büyük depresyon ve travma sonrası stres bozukluğunun tedavisi için üç deneysel psikiyatrik ilaçın hızlı incelemesini onayladı.
The U.S. Food and Drug Administration has expedited the review process for three novel psychedelic drug candidates. These experimental treatments are being developed with the aim of addressing major depressive disorder and post-traumatic stress disorder. The agency's decision allows for a faster evaluation of the potential therapeutic benefits of these compounds.
This expedited review signals a potential shift in how mental health conditions might be treated in the future, offering new avenues for patients with severe and persistent illnesses.
📌 Kaynak
Bu özet nbcnews kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →